Impressive response rates across tumor types with 'Trojan horse' drug

7 February 2019
institute-of-cancer-research-big

A drug dubbed the ‘Trojan horse’ of cancer treatments has shown promise in patients with different tumor types.

Among patients at the advanced, drug-resistant stage of the disease, more than a quarter with cervical and bladder tumors, and nearly 15% with ovarian and lung cancer, responded to the new treatment.

Called tisotumab vedotin (TV), the drug is being developed by biotech companies Genmab (OMX: GEN) and Seattle Genetics (Nasdaq: SGEN) in partnership with The Institute of Cancer Research, London.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology